O36.0135 Maternal care for anti-D [Rh] antibodies, third trimester, fetus 5

Name of the Condition

• Maternal care for anti-D [Rh] antibodies, third trimester, fetus 5
• ICD Code: O36.0135

Summary

This condition involves medical care and monitoring provided to a pregnant woman during the third trimester who has anti-D (Rh) antibodies and is carrying five fetuses. The focus is on managing the risk of hemolytic disease in the fetuses or newborns, which can occur if any fetus is Rh-positive. Care includes assessment of antibody levels, fetal monitoring, and planning for potential interventions to prevent or treat complications.

Causes

The presence of anti-D antibodies typically results from prior exposure to Rh-positive blood, such as during a previous pregnancy with an Rh-positive fetus, blood transfusion, or trauma. These antibodies can cross the placenta and attack the red blood cells of an Rh-positive fetus, leading to hemolysis.

Risk Factors

• Previous pregnancy with an Rh-positive fetus
• Blood transfusion with Rh-positive blood
• Trauma or procedures (e.g., amniocentesis) during pregnancy that may cause fetal-maternal bleeding
• Unknown prior sensitization (e.g., from unrecognized fetal-maternal hemorrhage)

Symptoms

• No direct maternal symptoms; the condition is identified through laboratory testing
• Potential fetal complications (e.g., anemia, hydrops fetalis) may develop, but these are not maternal symptoms

Diagnosis

Diagnosis involves testing the mother’s blood for anti-D antibody levels and determining the Rh status of the fetuses. Fetal monitoring, such as ultrasound or Doppler studies, may be used to assess for signs of hemolytic disease. In multiple gestations, each fetus’s Rh status and antibody impact must be evaluated.

Treatment Options

Treatment may include close monitoring of antibody levels and fetal well-being. Interventions could involve intrauterine transfusions for affected fetuses or planning for postnatal care, such as phototherapy or exchange transfusion for newborns with hemolytic disease. Rh immunoglobulin may be administered to prevent further sensitization in future pregnancies.

Prognosis and Follow-Up

Prognosis depends on the severity of antibody levels and fetal response. Regular follow-up with obstetric and maternal-fetal medicine specialists is essential to monitor fetal health and adjust care as needed. Delivery planning and neonatal support are critical for managing potential complications.

Complications

Complications may include severe fetal anemia, hydrops fetalis, or stillbirth in affected fetuses. Newborns may require intensive care for hemolytic disease, including jaundice or anemia. Maternal complications from multiple gestation, such as preterm labor, may also occur.

Lifestyle & Prevention

Preventive measures include Rh immunoglobulin administration after events that could cause fetal-maternal bleeding (e.g., trauma, procedures) to reduce sensitization risk. Avoiding unnecessary invasive procedures in Rh-negative women with antibodies may help minimize exposure.

When to Seek Professional Help

Seek medical attention if there are signs of preterm labor, reduced fetal movement, or abnormal fetal monitoring results. Prompt evaluation is necessary if new symptoms or complications arise during pregnancy.

Tips for Medical Coders

Document the number of fetuses (five) and the trimester (third) clearly. Ensure anti-D antibody presence and management are noted, as these are key to coding accuracy. Verify fetal Rh status and any interventions related to hemolytic disease risk.